55.21
Rhythm Pharmaceuticals Inc stock is traded at $55.21, with a volume of 685.47K.
It is up +5.58% in the last 24 hours and down -4.81% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
See More
Previous Close:
$52.29
Open:
$52.25
24h Volume:
685.47K
Relative Volume:
1.40
Market Cap:
$3.49B
Revenue:
$112.53M
Net Income/Loss:
$-258.91M
P/E Ratio:
-12.75
EPS:
-4.33
Net Cash Flow:
$-124.42M
1W Performance:
+7.58%
1M Performance:
-4.81%
6M Performance:
+1.21%
1Y Performance:
+41.13%
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
RYTM
Rhythm Pharmaceuticals Inc
|
55.21 | 3.49B | 112.53M | -258.91M | -124.42M | -4.33 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-05-25 | Resumed | Stifel | Buy |
Jan-02-25 | Initiated | Jefferies | Buy |
Dec-20-24 | Initiated | Oppenheimer | Outperform |
Oct-21-24 | Initiated | Guggenheim | Buy |
Sep-18-24 | Initiated | H.C. Wainwright | Buy |
Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
Jan-18-23 | Resumed | Canaccord Genuity | Buy |
Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
Jun-17-22 | Reiterated | Needham | Buy |
Mar-02-22 | Resumed | Stifel | Buy |
Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Dec-08-21 | Initiated | Wells Fargo | Overweight |
Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Sep-14-21 | Resumed | Goldman | Neutral |
Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
Jan-08-20 | Initiated | Goldman | Sell |
Jul-12-19 | Upgrade | Stifel | Hold → Buy |
Jul-08-19 | Initiated | Canaccord Genuity | Buy |
Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
Sep-07-18 | Resumed | Morgan Stanley | Overweight |
Jun-25-18 | Reiterated | Needham | Buy |
Jun-15-18 | Reiterated | Needham | Buy |
Oct-30-17 | Initiated | BofA/Merrill | Buy |
Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted To Setmelanotide For Treatment Of Hypothalamic Obesity In Japan - Marketscreener.com
Rhythm Pharmaceuticals receives orphan drug status in Japan - Investing.com
Rhythm Pharmaceuticals Receives Orphan-Drug Designation in Japan for Obesity Treatment - MarketWatch
Rhythm Pharmaceuticals Announces Orphan Drug Designation - GlobeNewswire
Breakthrough for Rare Obesity: Rhythm's Drug Wins Special Status in Japan - StockTitan
Charles Schwab Investment Management Inc. Has $24.65 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $66.00 Price Target at Needham & Company LLC - Defense World
Rhythm Pharmaceuticals EVP sells shares worth $3.86 million - Investing.com
Needham raises Rhythm Pharma stock target to $66, maintains buy By Investing.com - Investing.com UK
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Launch Research Collaboration on Fatigue in Craniopharyngioma Patients - Nasdaq
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration - GlobeNewswire
Major Breakthrough: Rhythm Pharma's New Research Tackles Devastating Fatigue in Brain Tumor Patients - StockTitan
Bank of New York Mellon Corp Sells 680 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Insider Sell Alert: EVP, Head of North America Jennifer Lee Sells Shares of Rhythm Pharmaceuticals Inc (RYTM) - GuruFocus.com
How To Trade (RYTM) - Stock Traders Daily
SBI Securities Co. Ltd. Invests $37,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Stifel maintains Buy on Rhythm Pharmaceuticals, $78 target By Investing.com - Investing.com Canada
Stifel maintains Buy on Rhythm Pharmaceuticals, $78 target - Investing.com India
Reviewing Wave Life Sciences (NASDAQ:WVE) & Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns Overweight Rating from Morgan Stanley - Defense World
Assessing Rhythm Pharmaceuticals: Insights From 10 Financial Analysts - Benzinga
Promising Outlook for Rhythm Pharmaceuticals: Buy Rating Backed by Positive Phase 3 Study Expectations and Market Potential - TipRanks
Stifel Nicolaus Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $68.27 - Defense World
HC Wainwright Brokers Raise Earnings Estimates for RYTM - Defense World
Citizens JMP maintains Rhythm Pharma Outperform, $81 target By Investing.com - Investing.com South Africa
Citizens JMP maintains Rhythm Pharma Outperform, $81 target - Investing.com India
Principal Financial Group Inc. Purchases 4,298 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Brokers Issue Forecasts for RYTM FY2026 Earnings - Defense World
Promising Market Potential for Rhythm Pharmaceuticals’ Setmelanotide in Treating Hypothalamic Obesity - TipRanks
Stifel raises Rhythm Pharmaceuticals stock to Buy with $78 target By Investing.com - Investing.com Canada
US High Growth Tech Stocks to Watch in March 2025 - Yahoo Finance
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates - MSN
Y Intercept Hong Kong Ltd Invests $328,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
HC Wainwright Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - Defense World
Rhythm Pharmaceuticals Faces Financial Risks Due to Convertible Preferred Stock Prioritization - MSN
Rhythm Pharmaceuticals stock target raised to $70 at H.C. Wainwright - Investing.com India
Learn to Evaluate (RYTM) using the Charts - Stock Traders Daily
Decoding Rhythm Pharmaceuticals Inc (RYTM): A Strategic SWOT Ins - GuruFocus.com
Needham & Company LLC Reaffirms “Buy” Rating for Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Posts Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $81.00 - MarketBeat
Rhythm Pharmaceuticals sets annual meeting for June 24 By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals sets annual meeting for June 24 - Investing.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns Buy Rating from Needham & Company LLC - MarketBeat
RHYTHM PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Purchased by Rhumbline Advisers - Defense World
Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Citizens JMP raises Rhythm Pharma stock target to $81 By Investing.com - Investing.com Canada
State of New Jersey Common Pension Fund D Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):